Somavert is a brand name of pegvisomant, approved by the FDA in the following formulation(s):
SOMAVERT (pegvisomant - injectable; subcutaneous)
Manufacturer: PHARMACIA AND UPJOHN
Approval date: March 25, 2003
Strength(s): 10MG/VIAL [RLD], 15MG/VIAL [RLD], 20MG/VIAL [RLD]
Has a generic version of Somavert been approved?
No. There is currently no therapeutically equivalent version of Somavert available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Somavert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Growth hormone antagonists
Patent 5,350,836
Issued: September 27, 1994
Inventor(s): Kopchick; John J. & Chen; Wen Y.
Assignee(s): Ohio University
The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants have growth inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype.Patent expiration dates:
- September 27, 2011✓
- September 27, 2011
Growth hormone antagonists
Patent 5,681,809
Issued: October 28, 1997
Inventor(s): Kopchick; John J. & Chen; Wen Y.
Assignee(s): Ohio University
The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants have growth inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype.Patent expiration dates:
- September 27, 2011✓
- September 27, 2011
Human growth hormone variants
Patent 5,849,535
Issued: December 15, 1998
Inventor(s): Cunningham; Brian C. & Lowman; Henry B. & Wells; James A. & Clark; Ross G. & Olson; Kenneth & Fuh; Germaine G.
Assignee(s): Genentech, Inc.
Human growth hormone variants, DNA encoding the variants, vectors, host cells, pegylated forms of the variants, as well as methods of making the variants are disclosed.Patent expiration dates:
- March 25, 2017✓
- March 25, 2017
Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
Patent 5,958,879
Issued: September 28, 1999
Inventor(s): Kopchick; John J. & Chen; Wen Y.
Assignee(s): Ohio University/Edison Biotechnology Institute
The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants have growth-inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to mammals. The antagonists may be used to reduce the activity of growth hormone in a mammal, especially one suffering from diabetes, diabetic retinopathy, diabetic nephropathy, a growth hormone secreting tumor, acromegaly, or gigantism.Patent expiration dates:
- September 27, 2011✓
- September 27, 2011
Method for inhibiting growth hormone action
Patent 6,057,292
Issued: May 2, 2000
Inventor(s): Cunningham; Brian C. & Lowman; Henry B. & Wells; James A. & Clark; Ross G. & Olson; Kenneth & Fuh; Germaine G.
Assignee(s): Genentech, Inc.
Human growth hormone variants are disclosed having enhanced affinity for the growth hormone receptor. Also disclosed are human growth hormone variants conjugated to one or more chemical groups, such as poly(ethylene glycol), which is believed to prolong the in vivo half-life of the variants.Patent expiration dates:
- September 21, 2015✓
- September 21, 2015
Methods for treating acromegaly and giantism with growth hormone antagonists
Patent 6,583,115
Issued: June 24, 2003
Inventor(s): John J.; Kopchick & Wen Y.; Chen
Assignee(s): Ohio University/Edison Biotechnology Institute
The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants-have growth-inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype. The invention also describes methods of treating acromegaly, gigantism, cancer, diabetes, vascular eye diseases (diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, retinopathy of sickle-cell anemia, etc.) as well as nephropathy and other diseases, by administering an effective amount of a growth hormone antagonist. The invention also provides pharmaceutical formulations comprising one or more growth hormone antagonists.Patent expiration dates:
- September 27, 2011✓
- September 27, 2011
See also...
- Somavert Consumer Information (Drugs.com)
- Somavert Consumer Information (Wolters Kluwer)
- Somavert Consumer Information (Cerner Multum)
- Somavert Advanced Consumer Information (Micromedex)
- Somavert AHFS DI Monographs (ASHP)
- Pegvisomant Consumer Information (Wolters Kluwer)
- Pegvisomant Consumer Information (Cerner Multum)
- Pegvisomant Subcutaneous Advanced Consumer Information (Micromedex)
- Pegvisomant AHFS DI Monographs (ASHP)
No comments:
Post a Comment